durvalumab
Showing 1 - 25 of 367
Pancreatic Ductal Adenocarcinoma Trial in Toronto (Durvalumab, Oleclumab)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Durvalumab
- Oleclumab
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Sep 22, 2023
NSCLC Trial (Durvalumab)
Not yet recruiting
- Non-small Cell Lung Cancer
- Durvalumab
- (no location specified)
Jun 22, 2023
NSCLC Trial in Iowa City (Durvalumab, Pharmacological ascorbate, Surgery (SOC))
Not yet recruiting
- Non-small Cell Lung Cancer
- Durvalumab
- +2 more
-
Iowa City, IowaUniversity of Iowa
Oct 10, 2023
Hepatocellular Carcinoma (HCC) Trial (Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE))
Not yet recruiting
- Hepatocellular Carcinoma (HCC)
- Durvalumab
- +2 more
- (no location specified)
Sep 11, 2023
Fibrolamellar Hepatocellular Carcinoma Trial in Baltimore (Durvalumab, DRP-104)
Not yet recruiting
- Fibrolamellar Hepatocellular Carcinoma
- Durvalumab
- DRP-104
-
Baltimore, MarylandJohns Hopkins SKCCC
Aug 30, 2023
Borderline Resectable Carcinoma, Biliary Tract Cancer Trial in Washington (Durvalumab, Tremelimumab, Gemcitabine)
Not yet recruiting
- Borderline Resectable Carcinoma
- Biliary Tract Cancer
- Durvalumab
- +4 more
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023
Biliary Tract Tumors, Immunotherapy Trial in Beijing (Durvalumab, Lenvatinib Oral Product, Chemotherapy)
Recruiting
- Biliary Tract Neoplasms
- Immunotherapy
- Durvalumab
- +2 more
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Jul 6, 2023
NSCLC Trial in Tampa, Philadelphia (Durvalumab, Carboplatin, Abequolixron)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Durvalumab
- +4 more
-
Tampa, Florida
- +1 more
Jun 9, 2023
Biliary Tract Cancers Trial (durvalumab)
Not yet recruiting
- Biliary Tract Cancers
- durvalumab
- (no location specified)
Jun 20, 2023
Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer Trial (Durvalumab, Monalizumab, Carboplatin or Cisplatin)
Not yet recruiting
- Small Cell Lung Cancer
- +2 more
- Durvalumab
- +3 more
- (no location specified)
Jun 5, 2023
Lung Cancer, Gastro-intestinal Cancer Trial in Houston (Durvalumab, Adagrasib)
Not yet recruiting
- Lung Cancer
- Gastro-intestinal Cancer
- Durvalumab
- Adagrasib
-
Houston, TexasM D Anderson Cancer Center
May 9, 2023
NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab
- +5 more
- (no location specified)
Aug 17, 2023
Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis Trial in Tianjin (Durvalumab, Surgery, Gemcitabine)
Recruiting
- Durvalumab
- +2 more
- Durvalumab
- +3 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jan 3, 2023
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer Trial in Boston (Durvalumab, Tremelimumab,
Not yet recruiting
- Resectable Hepatocellular Carcinoma
- +2 more
- Durvalumab
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 18, 2023
Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer Trial in United States (device, drug, radiation, procedure)
Active, not recruiting
- Non Small Cell Lung Cancer
- Stage III Non-small-cell Lung Cancer
- Durvalumab
- +4 more
-
Chicago, Illinois
- +3 more
Jan 18, 2023
Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma Trial in Winston-Salem (drug, other, diagnostic
Not yet recruiting
- Nonsmall Cell Lung Cancer Stage III
- Unresectable Non-Small Cell Lung Carcinoma
- Durvalumab
- +3 more
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
Jan 12, 2023
Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,
Recruiting
- Premenopausal Breast Cancer
- +2 more
- Goserelin
- +3 more
-
Taipei City, TaiwanDepartment of Oncology, National Taiwan University Hospital
Feb 7, 2023
Resectable Biliary Tract Cancer Trial in Tianjin (Cisplatin, Gemcitabine, Nab-paclitaxel)
Recruiting
- Resectable Biliary Tract Cancer
- Cisplatin
- +3 more
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital Airport Hospital
Nov 30, 2022
Urinary Bladder Tumors Trial run by the NCI (Durvalumab, Vicineum)
Recruiting
- Urinary Bladder Neoplasms
- Durvalumab
- Vicineum
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Unresectable Intrahepatic Cholangiocarcinoma Trial in Baltimore (Durvalumab, SNDX-6352)
Active, not recruiting
- Unresectable Intrahepatic Cholangiocarcinoma
- Durvalumab
- SNDX-6352
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Jan 10, 2023
Stomach Cancer, Adenocarcinoma Trial in Seoul (Durvalumab, Savolitinib)
Recruiting
- Stomach Cancer, Adenocarcinoma
- Durvalumab
- Savolitinib
-
Seoul, Korea, Republic ofSamsung Medical Center
Jan 10, 2023
Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable Trial in Boston (Gemcitabine, Cisplatin, Durvalumab)
Not yet recruiting
- Bile Duct Cancer
- +4 more
- Gemcitabine
- +3 more
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 23, 2023
Triple Negative Breast Cancer Metastatic Trial in Milano, Padova (Ceralasertib, Durvalumab, Nab-paclitaxel)
Recruiting
- Triple Negative Breast Cancer Metastatic
- Ceralasertib
- +2 more
-
Milano, Italy
- +1 more
Jan 16, 2023
Esophagus Adenocarcinoma Trial in Frankfurt (Durvalumab, FLOT, mFOLFOX-6)
Not yet recruiting
- Esophagus Adenocarcinoma
- Durvalumab
- +3 more
-
Frankfurt, GermanyInstitute of Clinical Cancer Research, University Cancer Center
Jan 26, 2023